| AstraZeneca Poaches R&D Head AstraZeneca hired a senior executive from rival Pfizer to head its drug research efforts, while Pfizer scrapped a short-lived experiment with having two heads of research. online.wsj.com |
Doctors Chafe As Medicare Cuts Loom The Senate could vote as soon as Wednesday to end debate on a bill to temporarily delay impending cuts to the program, but doctors are frustrated and limiting new Medicare patients. online.wsj.com |
FDA Panel Backs Proposed Epilepsy Drug A Food and Drug Administration panel Wednesday backed a proposed epilepsy drug called Potiga developed by Valeant Pharmaceuticals International and GlaxoSmithKline PLC. online.wsj.com |
Pfizer Acts on Growing Interest in Niche Drugs The Burrill Report submits: By Michael FitzhughPfizer (PFE) has agreed to by FoldRX, a privately held specialty drug developer targeting protein misfolding for an undisclosed initial payment plus milestones. The purchase builds on the drug giant's growing interest in niche drugs, a category it has begun to develop as a potential source of new revenues capable of partially stemming the losses it will incur when Lipitor goes off-patent in 2011. Complete Story » seekingalpha.com |
3 Clear Winners of ESMO 2010 Ohad Hammer submits:The ESMO meeting is the most important oncology conference in Europe. This year in particular, it included very interesting data that affected the sentiment towards many biotech companies. Here, I intend to focus on what I view as three clear winners from the conference: Seattle Genetics (SGEN), Arqule (ARQL) and Dendreon (DNDN). Seattle GeneticsComplete Story » seekingalpha.com |